ArticleClinical and molecular hepatology2024
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.
Article in Clinical and molecular hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- CSNK2B Expression Aligns with a GDF15-Associated Immune Molecular State in Hepatocellular Carcinoma.Biomedicines · 2026Article
- Varices and Hemorrhagic Events during Atezolizumab-bevacizumab Treatment: Reassurance with Caveats for Prognosis.Gut and liver · 2026Article
- Correspondence to letter to the editor on "Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma".Clinical and molecular hepatology · 2026Article
- Biomarker-guided immuno-angiogenic therapy in biliary tract cancer: insights from IMbrave151.Journal of gastrointestinal oncology · 2026Article
- Low Tumor Burden Predicts Benefit from Transarterial Treatment in Hepatocellular Carcinoma with Extrahepatic Metastasis: A Nationwide Cohort Study.Liver cancer · 2026Article
- Baseline and dynamic cytokines as biomarkers for immune checkpoint and anti-VEGF therapy in advanced hepatocellular carcinoma.ESMO gastrointestinal oncology · 2026Article
- Perioperative immunotherapy for hepatocellular carcinoma: adjuvant, neoadjuvant, and biomarker-guided strategies.Frontiers in medicine · 2026Review
- Immune resistance in hepatobiliary and pancreatic cancers: rethinking the tumor microenvironment beyond checkpoint blockade.Frontiers in immunology · 2026Article
- A novel link between tumor cell metabolism and patient prognosis: Editorial on "Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway".Clinical and molecular hepatology · 2026Article
- Prognostic Significance of Glypican-3 Expression in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab.Cancers · 2025Article
- Advances and challenges in immunotherapy and molecular imaging for hepatocellular carcinoma.Discover oncology · 2025Review
- Bulk and Single-Cell Transcriptomes Reveal Exhausted Signature in Prognosis of Hepatocellular Carcinoma.Genes · 2025Article
- Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors.Discover oncology · 2025Review
- Advances in cancer immunotherapy: historical perspectives, current developments, and future directions.Molecular cancer · 2025Review
- Article
- Correspondence to editorial on "Integrated molecular characterization of sarcomatoid hepatocellular carcinoma".Clinical and molecular hepatology · 2025Article
- Advancing the management of hepatocellular carcinoma: surrogate markers and predictive biomarkers for survival on immunotherapy.Hepatobiliary surgery and nutrition · 2025Article
- Reply to correspondence on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".Clinical and molecular hepatology · 2025Article
- Hepatic Metabolic Signature and Its Association with the Response to Immunotherapy in Hepatocellular Carcinoma.ImmunoTargets and therapy · 2025Article
- Monocyte/macrophage-derived IL-15 activates STAT5 to trigger the EFNA1/NCOA2-positive feedback loop, facilitating retinal angiogenesis in high-glucose environments.Molecular vision · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
Abstract
BACKGROUND/
aimsCombination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, the lack of predictive biomarkers and limited understanding of response mechanisms remain a challenge.
methodsUsing data from the IMbrave150plus cohort, we applied an immune signature score (ISS) predictor to stratify HCC patients treated with atezolizumab plus bevacizumab or with sorafenib alone into potential high and low response groups. By applying multiple statistical approaches including a Bayesian covariate prediction algorithm, we refined the signature to 10 key genes (ISS10) for clinical use while maintaining similar predictive power to the full model. We further validated ISS10 in an independent HCC cohort treated with nivolumab plus ipilimumab.
resultsThe study identified a significant association between the ISS and treatment response. Among patients classified as high responders, those treated with the atezolizumab plus bevacizumab combination exhibited improved overall and progression-free survival as well as better objective response rate compared to those treated with sorafenib. We also observed a significant correlation between ISS10 and response to nivolumab plus ipilimumab treatment. Analysis of immune cell subpopulations revealed distinct characteristics associated with ISS subtypes. In particular, the ISS10 high subtype displayed a more favorable immune environment with higher proportions of antitumor macrophages and activated T-cells, potentially explaining its better response.
conclusionOur study suggests that ISS and ISS10 are promising predictive biomarkers for enhanced therapeutic outcomes in HCC patients undergoing combination immunotherapy. These markers are crucial for refining patient stratification and personalized treatment approaches to advance the effectiveness of standard-of-care regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.